Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nebulizers Clear all
Completed Not applicable Interventional Results available

Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis

NCT02029040
View directory record Official record
Conditions
Acute Bronchiolitis
Interventions
3% Hypertonic Saline, 0.9 % normal saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Months to 12 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Systemic Inflammatory Response to CCRE

NCT02847247
View directory record Official record
Conditions
Healthy
Interventions
CCRE
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RCT2100, Placebo, Ivacaftor
Drug · Other
Lead sponsor
ReCode Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 11:34 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

NCT03496623
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled treprostinil solution, Placebo solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

NCT00754546
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 28, 2013 · Synced Sep 10, 2026, 11:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim, Placebo, Molgramostim Open-label
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

NCT00558844
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Arikayce™ 560 mg, Placebo for 560 mg, Arikayce™ 70 mg, Arikayce™ 140 mg, Placebo for 70 mg / 140 mg
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
6 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

NCT01880723
View directory record Official record
Conditions
Cystic Fibrosis, Healthy
Interventions
Albuterol, Placebo saline
Drug
Lead sponsor
University of Arizona
Other
Eligibility
15 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04542057
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
77
States / cities
Alabaster, Alabama • Andalusia, Alabama • Jasper, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04535986
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Peoria, Arizona • Tempe, Arizona • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Nebulized Nasal Steroids

NCT07270302
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
nebulized budesonide via NasoNeb, budesonide lavage via NeilMed
Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 10, 2026, 11:34 PM EDT
Terminated Not applicable Interventional Results available

Breath-Actuated Nebulizer Versus Conventional Continuous-Output Nebulizer in Pediatric Asthma Patients

NCT01045174
View directory record Official record
Conditions
Asthma
Interventions
Nebulizer (breath-actuated versus conventional continuous-output)
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
1 Year to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 10, 2026, 11:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

NCT06526923
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2
Combination Product
Lead sponsor
Spirovant Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Kansas City, Kansas • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

Aerosolized Albuterol Use in Severe BPD

NCT02766673
View directory record Official record
Conditions
Severe Bronchopulmonary Dysplasia
Interventions
Albuterol Sulfate, Sterile Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation

NCT01515995
View directory record Official record
Conditions
Asthma
Interventions
Nebulized magnesium sulfate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial

NCT01696214
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone 250 mg/salmeterol 50 mg, Montelukast 10mg, Theophylline 400 mg, ipratropium
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed No phase listed Observational

Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease

NCT00903955
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
7% hypertonic saline
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 82 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF

NCT01303068
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
13C urea breath test Kit
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 10, 2026, 11:34 PM EDT
Recruiting Phase 4 Interventional

Hypertonic Saline for MAC

NCT04921943
View directory record Official record
Conditions
Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Interventions
Hypertonic saline, Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

NCT03202394
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
BIO-11006, Placebo
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 10, 2026, 11:34 PM EDT